Entasis Therapeutics (NASDAQ:ETTX – Get Rating) posted its quarterly earnings results on Wednesday. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.09), MarketWatch Earnings reports.
ETTX opened at $1.90 on Friday. The stock has a market capitalization of $90.92 million, a PE ratio of -1.74 and a beta of 1.60. The firm’s fifty day moving average price is $1.83 and its 200 day moving average price is $2.17. Entasis Therapeutics has a 12-month low of $1.40 and a 12-month high of $3.88.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its holdings in Entasis Therapeutics by 3.5% in the fourth quarter. Renaissance Technologies LLC now owns 323,345 shares of the company’s stock valued at $708,000 after acquiring an additional 10,800 shares in the last quarter. Geode Capital Management LLC raised its holdings in Entasis Therapeutics by 10.5% in the fourth quarter. Geode Capital Management LLC now owns 102,927 shares of the company’s stock valued at $225,000 after acquiring an additional 9,759 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Entasis Therapeutics by 214.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 81,904 shares of the company’s stock valued at $179,000 after acquiring an additional 55,834 shares in the last quarter. Susquehanna International Group LLP acquired a new stake in Entasis Therapeutics in the fourth quarter valued at $143,000. Finally, Jane Street Group LLC acquired a new stake in Entasis Therapeutics in the third quarter valued at $107,000. 9.27% of the stock is currently owned by hedge funds and other institutional investors.
Entasis Therapeutics Company Profile (Get Rating)
Entasis Therapeutics Holdings Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii.
- Get a free copy of the StockNews.com research report on Entasis Therapeutics (ETTX)
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
- Iridium Communications Stock is Ready to Return to Orbit
- There’s An Institutional Floor In Keurig Dr. Pepper
- Ford Falls Despite Optimistic Outlook
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.